Cirio advised Intervacc with its directed share issue to institutional investors

Cirio advised Intervacc AB (publ), listed on Nasdaq First North Growth Market, in connection with its directed share issue to institutional investors.

The board of directors of Intervacc AB (publ) has, based on the authorization granted by the annual meeting on 11^th of June 2019, resolved on a directed share issue to a limited number of institutional investors. The subscribers of the share issue are AP4 (fjärde AP-fonden), Robur and Healthinvest.

The directed share issue aims to finance continued commercialization of Strangvac^® and the development of the Company’s other vaccines.

Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern recombinant vaccines within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and the Swedish University of Agriculture where the foundation was laid for the technology platform that forms the basis of the Company’s research and development work. The Intervacc share is listed on Nasdaq First North Growth Market.

Cirio advised Intervacc through a team lead by Per Hedman (M&A/Life sciences), together with Maria Arnoldsson, Anton Knifström and Nina Lannsjö (Capital Markets and Public M&A).

For more information, please contact: